JP2023513015A - 異常な細胞成長を処置するための併用療法 - Google Patents

異常な細胞成長を処置するための併用療法 Download PDF

Info

Publication number
JP2023513015A
JP2023513015A JP2022546004A JP2022546004A JP2023513015A JP 2023513015 A JP2023513015 A JP 2023513015A JP 2022546004 A JP2022546004 A JP 2022546004A JP 2022546004 A JP2022546004 A JP 2022546004A JP 2023513015 A JP2023513015 A JP 2023513015A
Authority
JP
Japan
Prior art keywords
inhibitor
administered
kras
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513015A5 (enExample
Inventor
ジョナサン エー． パクター，
シルビア コマ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of JP2023513015A publication Critical patent/JP2023513015A/ja
Publication of JP2023513015A5 publication Critical patent/JP2023513015A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022546004A 2020-01-31 2021-01-28 異常な細胞成長を処置するための併用療法 Pending JP2023513015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062968615P 2020-01-31 2020-01-31
US62/968,615 2020-01-31
US202063115433P 2020-11-18 2020-11-18
US63/115,433 2020-11-18
PCT/US2021/015401 WO2021154929A1 (en) 2020-01-31 2021-01-28 Combination therapy for treating abnormal cell growth

Publications (2)

Publication Number Publication Date
JP2023513015A true JP2023513015A (ja) 2023-03-30
JP2023513015A5 JP2023513015A5 (enExample) 2024-01-22

Family

ID=77079417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546004A Pending JP2023513015A (ja) 2020-01-31 2021-01-28 異常な細胞成長を処置するための併用療法

Country Status (11)

Country Link
US (1) US20230103007A1 (enExample)
EP (1) EP4096671B1 (enExample)
JP (1) JP2023513015A (enExample)
KR (1) KR20230011908A (enExample)
CN (1) CN115279376A (enExample)
AU (1) AU2021213753A1 (enExample)
BR (1) BR112022015161A2 (enExample)
CA (1) CA3168648A1 (enExample)
IL (1) IL295117A (enExample)
MX (1) MX2022009347A (enExample)
WO (1) WO2021154929A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
EP4062914A4 (en) 2019-11-18 2024-01-17 Inxmed (Nanjing) Co., Ltd. USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
AU2021206684B2 (en) 2020-01-10 2024-01-18 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
EP4101453A4 (en) 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
ES3049298T3 (en) * 2020-08-03 2025-12-16 Inxmed Nanjing Co Ltd Solid form of compound
WO2022165142A1 (en) * 2021-01-29 2022-08-04 Mirati Therapeutics, Inc. Combination therapies
US12280055B2 (en) * 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
TW202313044A (zh) * 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
CN114133355B (zh) * 2021-11-29 2023-09-15 郑州大学第一附属医院 一种2-苯基-1h-苯并咪唑类衍生物及其应用
JP2024545147A (ja) * 2021-12-10 2024-12-05 ▲應▼世生物科技（南京）有限公司 腫瘍治療の医薬組合せ及び使用
WO2023108110A2 (en) * 2021-12-10 2023-06-15 Verastem, Inc. Combination therapy for treating abnormal cell growth
CA3252402A1 (en) * 2022-02-28 2025-07-07 Wigen Biomedicine Technology (shanghai) Co., Ltd. COMPOUND USED AS A FAK INHIBITOR AND ITS USE
JP7565132B2 (ja) * 2022-04-20 2024-10-10 中外製薬株式会社 がんの治療又は予防用医薬
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
CN119451679A (zh) * 2022-08-24 2025-02-14 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
CN119947725A (zh) * 2022-09-30 2025-05-06 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
JP2026503267A (ja) * 2023-01-06 2026-01-28 エラスカ，インク． Ｒａｆ阻害剤およびｋｒａｓ ｇ１２ｃ阻害剤の併用療法
CN115845065A (zh) * 2023-01-09 2023-03-28 江苏省原子医学研究所 Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途
US12254987B2 (en) * 2023-03-23 2025-03-18 Certis Oncology Solutions, Inc. Artificial intelligence for identifying one or more predictive biomarkers
WO2024199466A1 (zh) * 2023-03-31 2024-10-03 应世生物科技(南京)有限公司 提高大分子药物在肿瘤组织中的浓度的方法
WO2025106901A1 (en) * 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
WO2025149017A1 (zh) * 2024-01-11 2025-07-17 四川弘合生物科技有限公司 一种包含榄香烯和激酶抑制剂的药物
WO2025157162A1 (zh) * 2024-01-22 2025-07-31 应世生物科技(南京)有限公司 Fak抑制剂与kras g12c抑制剂的联用
WO2025261307A1 (zh) * 2024-06-17 2025-12-26 首药控股(北京)股份有限公司 治疗肿瘤的药物组合及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
WO2015120289A1 (en) * 2014-02-07 2015-08-13 Verastem, Inc. Methods and compositions for treating abnormal cell growth
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US11286469B2 (en) * 2017-11-09 2022-03-29 Wisconsin Alumni Research Foundation Combination chemotherapy for the treatment of cancer
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
BR112022010278A2 (pt) * 2019-11-27 2022-10-04 Turning Point Therapeutics Inc Terapia combinada que envolve compostos macrocíclicos de diarila

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOVERY, vol. 10, JPN6025002583, 9 January 2020 (2020-01-09), pages 54 - 71, ISSN: 0005701214 *
CANCER RES, vol. 73, no. 13, JPN6025002586, 2013, pages 4050 - 4060, ISSN: 0005701217 *
EJNMMI RESEARCH, vol. Vol.3:67, JPN6025002587, 2013, pages 1 - 11, ISSN: 0005701218 *
LUNG CANCER, vol. 139, JPN6025002584, 4 November 2019 (2019-11-04), pages 60 - 67, ISSN: 0005701215 *
NATURE, vol. 575, JPN6025002580, 2019, pages 217 - 223, ISSN: 0005701213 *
PLOSONE, vol. Vol.9, No.11:e113217, JPN6025002585, 2014, pages 1 - 16, ISSN: 0005701216 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Also Published As

Publication number Publication date
US20230103007A1 (en) 2023-03-30
BR112022015161A2 (pt) 2022-10-11
EP4096671A4 (en) 2024-02-28
IL295117A (en) 2022-09-01
EP4096671A1 (en) 2022-12-07
WO2021154929A1 (en) 2021-08-05
CN115279376A (zh) 2022-11-01
KR20230011908A (ko) 2023-01-25
EP4096671B1 (en) 2026-05-06
CA3168648A1 (en) 2021-08-05
AU2021213753A1 (en) 2022-08-04
MX2022009347A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
EP4096671B1 (en) Combination therapy for treating abnormal cell growth
JP7289807B2 (ja) 異常な細胞成長を処置するための方法および組成物
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
JP7634351B2 (ja) 治療組成物、組み合わせ、及び使用方法
US20250049792A1 (en) Combination therapy for treating abnormal cell growth
US20230201198A1 (en) Methods of treating abnormal cell growth
JP2022172480A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406